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ABSTRACT
Pharmacoeconomic analysis is aimed at 
supporting choices between alternatives 
available for the efﬁcient management 
of speciﬁc conditions. Aim of the paper 
is to provide an overview of the main 
features of pharmacoeconomic evalua-
tions, with the objective of providing the 
reader with the basic tools necessary 
to read and interpret or to design and 
conduct a pharmacoeconomic analysis 
in RA and in other rheumatic diseases. 
The paragraphs will cover in detail the 
deﬁnition of health economic evaluation 
and pharmacoeconomics, the alterna-
tives to be compared, the perspective of 
the analysis, costs and effects (present-
ing in detail direct costs and effects, in-
direct costs and effects, intangible costs 
and effects and source of data), and 
pharmacoeconomic techniques.
Pharmacoeconomic analyses have to 
be conducted accurately to provide val-
uable information to guide the choice of 
options representing the best value for 
money without compromising the qual-
ity of care delivered. For this reason, as 
these analyses generally present some 
limitations, a very close and strong rela-
tionship between pharmacoeconomists 
and clinicians is crucial both in the de-
sign of pharmacoeconomic studies and 
in the interpretation of their results, and 
also in the development of more satis-
factory methods and indicators.
Introduction 
The high economic burden attributable 
to rheumatologic diseases and availabil-
ity of new treatment options consuming 
a greater portion of health care budgets 
have stimulated increasing attention to-
ward pharmacoeconomic evaluations to 
identify more efﬁcient treatments (1-7). 
A similar trend has been observed in the 
ﬁeld of medical devices and major tech-
nologies with development of health 
technology assessment (HTA) analy-
ses (8-10). As an example, signiﬁcant 
progress in understanding the immun-
opathogenesis of rheumatoid arthritis 
(RA), combined with advances in bio-
technology, has led to the development 
of new drugs, such as the inhibitors of 
the pro-inﬂammatory cytokine tumour 
necrosis factor α (TNF-α) (11). Intro-
duction of TNF-α inhibitors has pro-
vided important new treatment options 
in the therapeutic approach for RA and, 
meanwhile, has sensitively impacted on 
the costs of treatment of these patients 
(12-17). 
According to the results of a study con-
ducted by Lundkvist and colleagues 
(14), there are around 6.7 million pa-
tients with RA in Europe (including the 
Russian Federation and Turkey), Aus-
tralia, South Africa and North America. 
The total cost of this disease in 2006 
was €45 billion in Europe and €42 bil-
lion in the US, and was close to €100 
billion in all countries considered in the 
review. Of these, direct health care costs 
accounted for about €42 billion, repre-
senting around 1.4% of total health care 
expenditures in these Countries. In the 
same study, Lundkvist and colleagues 
(14) have also shown that the costs of 
RA varied with country, with an aver-
age of €17,000 per patient per year in 
Western Europe, and €5,000 in Central 
and Eastern Europe. The total cost of 
RA changes between countries for many 
regions, but one of the most relevant is 
the different use of biologic treatments, 
which has sensitively increased the cost 
of treatment (12-16, 18).
Pharmacoeconomic analysis is aimed at 
supporting choices between alternatives 
available for the rational management of 
speciﬁc conditions. The rational man-
agement of diseases is in ﬁrst instance 
deﬁned with respect to its quality and ef-
fectiveness. However, a further dimen-
sion to be considered is the efﬁciency of 
a treatment/programme compared with 
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the available alternatives. This dimen-
sion can be considered through pharma-
coeconomic evaluations. Two different 
types of efﬁciency can be considered: 
technical efﬁciency and allocative ef-
ﬁciency. The technical efﬁciency may 
be crudely deﬁned as the capacity of 
a programme to reach effects with the 
minimum cost possible. Allocative efﬁ-
ciency refers to a goal to keep opportu-
nity costs at a minimum possible level. 
This has to do with the distribution and 
re-distribution of resources, consider-
ing various perspectives altogether (e.g. 
society). Accordingly, public decision 
makers are often concerned with al-
locative efﬁciency, while private parties 
(e.g., industry) are generally interested 
in technical efﬁciency. The choice of 
the perspective may then inﬂuence the 
choice of the type of efﬁciency and, as 
a consequence, the technique of a phar-
macoeconomic evaluation (19).
The following sections of this article 
provide an overview of the main fea-
tures of pharmacoeconomic evalua-
tions, with the objective of providing 
the reader with basic background tools 
necessary to read and interpret and/or 
to design and conduct a pharmacoeco-
nomic analysis in RA and in other rheu-
matic diseases.
Deﬁnition of health economic 
evaluation and pharmacoeconomics
Broadly speaking, economic evaluation 
can be deﬁned as the approach aimed 
to compare costs and consequences (ef-
fects) of two or more alternative course 
of actions, which in healthcare general-
ly include options to diagnose, prevent 
or treat a disease (19). In particular, 
pharmacoeconomics refers to health 
economic evaluations in which at least 
one of the compared options includes 
a drug therapy. To conduct an accurate 
pharmacoeconomic analysis it is neces-
sary to clarify and decide on some key 
parameters, which are described below.
Alternatives to be compared
One crucial step for the conduction of 
a pharmacoeconomic analysis consists 
of deciding the alternative options to 
consider for the comparison. Pharma-
coeconomics refers to health economic 
evaluations in which at least one of 
the compared options includes a drug 
therapy. The alternative options may 
include any clinically relevant and 
available intervention such as a drug 
therapy, a different type of intervention 
(e.g., surgery) or the option of no in-
tervention.
Perspective of the analysis
Important to any pharmacoeconomic 
analysis is a comprehensive estimation 
of all costs and effects related to the dis-
ease and its management. The effects and 
the costs of using an intervention depend 
on which perspective, or point of view, 
of the analysis is adopted. Clarifying the 
perspective of the analysis is necessary 
because an item can be a cost from one 
point of view, but not from another point 
of view. For example, loss of productiv-
ity attributable to the disease or to its 
treatment is a cost for the patients and 
more broadly for the society; however, 
this is not a cost for the third party payer 
(e.g. National Health Service - NHS). 
The inclusion of loss of productivity or 
sick leave in pharmacoeconomic evalua-
tions targeted to rheumatologic diseases 
increases signiﬁcantly the costs from the 
perspective of the patient and of the so-
ciety (20, 21). For instance, according to 
a pharmacoeconomic study conducted 
in Italy to assess the efﬁciency of bio-
logic treatment of patients with psori-
atic arthritis (21), the mean six-months 
health care cost (visits to physician, 
medications, hospitalisations, diagnos-
tic procedures, etc.) was €883 per pa-
tient considering the perspective of the 
NHS. When adopting the perspective 
of the society, the total cost increased to 
€1,500 per patient-6 months, because 
it included also indirect costs (such as 
short-term absence/sick leave).
The costs due to time lost from work or 
other usual activities (e.g., housework, 
study) are typically not taken into ac-
count if the perspective of the third 
party payer is adopted, as it does not 
pay for these costs. Instead, a policy 
maker could be interested also in these 
costs borne from different perspectives, 
such as patients, caregivers, third party 
payer and healthcare provider (societal 
perspective).
The choice of the perspective may in-
ﬂuence the choice of the either techni-
cal or allocative type of efﬁciency and, 
as a consequence, the technique used in 
a pharmacoeconomic study.
Costs and effects
Once the alternatives and the perspec-
tive of the analysis are clariﬁed, costs 
and effects relevant for the analysis can 
be identiﬁed. After identifying them, 
costs and effects must be measured 
and, when appropriate, quantiﬁed in 
monetary terms. Both costs and effects 
can be categorised as direct, indirect 
and intangible.
The inclusion of each category of costs 
into the analysis depends on a number 
of factors, including the relevance of 
each item on the total cost (e.g. the loss 
of productivity and the cost of biologic 
therapy contribute importantly to the 
total cost in rheumatologic diseases) 
(12-16, 20, 21), the perspective of the 
analysis (e.g. the societal perspective 
requires the computation of loss of pro-
ductivity, while the perspective of the 
third party payer does not require this 
item) and the availability of data (e.g. 
quantiﬁcation of loss of productivity is 
particularly difﬁcult to be performed). 
The adoption of standards for economic 
evaluation or matrix of cost domains 
applied to rheumatic diseases would 
greatly facilitate national and interna-
tional comparisons (22).
A brief description of costs and effects 
category is reported below.
Direct costs and effects
Direct costs and effects refer to items 
that are more closely related with the 
disease and its treatment. For instance, 
costs of drug treatment, hospitalisa-
tions, surgery, physiotherapy, costs for 
the monitoring and treating toxicity. Di-
rect costs can be further divided in two 
subgroups: medical costs (drugs, spe-
cialist consultations, hospitalisations, 
etc.) and non-medical costs (patient’s 
travel costs, formal care at home, etc.).
Effects can be expressed using differ-
ent outcome measures. Final outcomes 
can include radiological damage, swol-
len join count, functional capacity, 
Disease Activity Score, disability-days 
averted, lives saved, life of years saved 
(12, 23). However, sometimes biomar-
kers are used, e.g. C-reactive protein, 
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erythrocyte sedimentation rate (24). A 
biomarker is a biochemical or clinical 
parameter that is related to a ﬁnal out-
come (25). Biomarkers are frequently 
employed as surrogate endpoints in 
studies targeted to new health interven-
tions. The use of biomarkers is general-
ly more convenient than the use of ﬁnal 
outcomes, because this may facilitate 
the reduction of the costs of the study 
or even to make the study feasible, due 
to the need of a reduced size of the 
study sample and a shorter study dura-
tion. However, to obtain reliable results 
on the efﬁciency of a treatment, it is 
fundamental that the biomarker used to 
estimate the efﬁcacy of a treatment is 
valid and correlated with the ﬁnal out-
come of interest (e.g. disease activity 
and radiological damage).
Indirect costs and effects
Indirect costs and effects refer to pro-
ductivity variation due to the disease 
and its management. Costs are asso-
ciated with lost or impaired ability to 
work or engage in leisure activities, 
while effects are associated with gain 
or improvement. In conditions such 
as RA, indirect costs are extremely 
important; historically, indirect costs 
accounted for the majority of costs of 
RA, which remains the case in many 
patients at this time (26-29).
The quantiﬁcation of indirect costs and 
effects is complex and often difﬁcult. 
There are at least two possible ways 
that can be used to quantify indirect 
costs: the human capital approach and 
the friction cost method. Through the 
human capital approach, the loss of pro-
ductivity attributable to the disease and 
its consequences in terms of absentee-
ism from work is converted in monetary 
terms multiplying the time (days, hours) 
lost from work due to the disease by the 
patients’ remuneration. However, there 
are some caveats to be considered when 
using the human capital approach: ﬁrst, 
the value of time lost is quantiﬁed only 
on individuals who have paid work, 
while there are subjects that do not have 
a paid work, e.g. students or house-
wives, but who can have productivity 
losses due to their condition. Further-
more, these valuations could overesti-
mate the true cost to society if individu-
als are to be taken out of the workforce 
because of their disease. For example, 
for short-term absences, losses of pro-
ductivity could be compensated for by 
the worker when returning at work, or 
by her/his colleagues. For long-term 
absence, the employer is likely to hire 
a replacement worker. Therefore, the 
amount of productivity lost depends on 
the time and cost of organising the re-
placement (19). 
The friction cost method has been pro-
posed as an alternative to the human 
capital approach (30). The basic idea 
is that the amount of production lost 
due to disease depends on the time or-
ganisations need to restore the initial 
production level. This friction period 
is likely to differ by location, industry, 
ﬁrm, and category of worker (19).
In addition, indirect costs may not in-
clude a full accounting of the impact of 
disease. For example, even if patients 
go to work, they could work with less 
productivity because of their disease, 
known as “presenteeism”. Presentee-
ism is relevant especially in patients 
with RA, however, it is usually not in-
cluded in the assessments of indirect 
costs. In many contexts, such as RA, 
the condition could also interfere with 
patients’ career and related increases in 
income that would otherwise have been 
earned without the disease (31).
Moreover, the lack of productivity re-
lated to home care provided by a rela-
tive or friend, known as informal care, 
should be considered as well, but usu-
ally is not included. 
Intangible costs and effects
Intangible costs and effects refer to 
consequences of a disease and of a 
medical programme in individuals’ 
Quality of Life (QoL). Until around 
seven decades ago, the main objective 
of medical interventions focused on 
the improvement of physical aspects of 
life, e.g. amelioration of speciﬁc symp-
toms and signs of diseases, increase 
of quantity of life. Over the years, ad-
vancements in the medical and related 
sciences have allowed to dramatically 
improve the outcome and prognosis of 
many diseases. As a result, years have 
been added to the life of individuals. 
However, not necessarily the quality of 
life could always be improved as well.
During the Eighties the parameter of 
QoL was recognised to be important 
for measuring health and outcomes of 
interventions, together with the tradi-
tional and standard clinical parameters. 
Initially, the focus was on complement-
ing or balancing the emphasis that had 
been placed on survival time, especially 
in areas such as oncology. In addition, 
there was a move to monitor long-term 
care for chronically ill people, particu-
larly when cure was not seen to be an 
option, such as in rheumatic diseases. 
The focus was shifted to consideration 
of the patient’s perspective on his QoL, 
in contrast with the opinions of physi-
cians or other healthcare profession-
als. It was recognised that changes in 
the patient’s QoL are among the main 
determinants of demand for care, com-
pliance with treatment regimen and 
satisfaction. It was understood that 
this parameter, which allows the as-
sessment of patients’ health according 
to their perception, is to be taken into 
account in the evaluation of healthcare. 
As a consequence, considerable re-
search has been conducted to produce 
appropriate instruments and to assess 
QoL in many clinical conditions. From 
1990 to 1999, for example, the number 
of published reports about the develop-
ment or evaluation of QoL instruments 
rose from 144 to 650 (32).
 Although easy to conceive in an ab-
stract manner, QoL is difﬁcult to deﬁne. 
Numerous attempts have been made in 
this regard. Of the several available, 
the most widely used deﬁnition is the 
one by the World Health Organisation 
(33): “Quality of Life is individuals’ 
perception of their position in life in 
the context of the culture and value sys-
tems in which they live and in relation 
to their goals, expectations, standards, 
concerns. It is a broad ranging concept, 
incorporating in a complex way indi-
viduals’ physical health, psychological 
state, level of independence, social re-
lationships, personal beliefs, and their 
relationships to salient features of the 
environment. This deﬁnition highlights 
the view that quality of life is subjec-
tive, includes both positive and nega-
tive factors of life and is multi-dimen-
sional”. In healthcare, the term Health 
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Related Quality of Life (HRQoL) is 
frequently used. More speciﬁcally, 
HRQoL can be deﬁned as the “impact 
of an accident/disease and of its man-
agement on the involved individuals’ 
QoL” (34). Hence, HRQoL is more 
focused on QoL related to phenomena 
that involve individuals’ health. 
Among the instruments available to 
assess HRQoL we can distinguish be-
tween disease-speciﬁc and generic in-
struments, and between proﬁles and 
indexes (35, 36). 
Disease-speciﬁc instruments have been 
developed for one particular condition 
or a range of related conditions, e.g. the 
arthritis impact measurement scale (37). 
Aim of these instruments is to obtain 
speciﬁc information on the target condi-
tion. However, comparability of HRQoL 
is compromised when studying different 
diseases. Furthermore, these instruments 
do not give a comprehensive measure of 
HRQoL and therefore cannot be used to 
compare the cost-effectiveness of pro-
grammes in different disease areas. On 
the other side, generic instruments are 
aimed to be applicable to a wide range 
of populations deﬁned by age and gen-
der, type and severity of disease, culture. 
The SF-36 (38) and the EQ-5D (39) are 
among the most frequently used generic 
QoL instruments worldwide. However, 
in some situations, these instruments 
may exhibit a lower precision or respon-
siveness to changes than disease-specif-
ic measures. Generally, the use of a bat-
tery of instruments, including a generic 
questionnaire and a condition-speciﬁc 
one can allow to combine the different 
and complementary advantages of each 
instrument.
Proﬁles describe HRQoL through a 
number of dimensions of health, while 
indexes allow to summarise in one 
number the information attributable 
to more dimensions. Because they are 
more informative than indexes, proﬁles 
may be more useful in clinical settings. 
On the other hand, proﬁles present 
some disadvantages for economic eval-
uations, because they generally provide 
different information that cannot be 
compared. Furthermore, to be inserted 
in a pharmacoeconomic analysis, the 
index should be indicative of the pref-
erences of individuals for the outcomes. 
These preferences can be included in a 
utility index. Utility can be deﬁned as 
the preference that individuals have 
given to health states. A utility index is 
expressed on a scale anchored between 
0 (death) and 1 (perfect health). Utilities 
can be measured directly using speciﬁc 
techniques, such as the standard gamble 
and time trade-off (19, 40), or derived 
from health state systems, such as those 
developed for the EQ-5D or the Health 
Utility Index (39, 41, 42).
The EQ-5D is a generic instrument that 
includes both a proﬁle and an index, 
and allows to obtain an utility index 
(39). The standard version of the EQ-
5D (EQ-5D-3L) consists of two parts. 
One part includes a proﬁle (or descrip-
tive system) with ﬁve dimensions (mo-
bility, self-care, usual activities, pain/
discomfort, anxiety/depression), which 
allow describing health according to 
three levels of severity (no problems, 
some problems, severe problems). The 
second part contains a Visual Analogue 
Scale to provide with an index rang-
ing from 0 (worst level of HRQoL) to 
100 (best level of HRQoL) a measure 
of individuals’ health perception. Fur-
thermore, the EQ-5D was developed to 
obtain a utility index through the con-
version of the answers provided with 
the proﬁle into one index anchored be-
tween 0 (corresponding to death) and 1 
(corresponding to perfect health). The 
utility index can be used to calculate the 
Quality Adjusted Life Years (QALY) 
parameter (43), which is generally used 
to conduct Cost-Utility Analyses.
In order to improve the potentialities of 
the EQ-5D, new versions of this instru-
ment have been recently developed in a 
number of different languages: the EQ-
5D-Y, to be self-completed by children 
and adolescents aged from 8 years (44- 
46), and the EQ-5D-5L, in which 2 lev-
els of severity are added in each domain 
(47, 48).
Source of data
The availability of good quality data on 
the effectiveness of the options to be 
compared is crucial to conduct an ac-
curate pharmacoeconomic evaluation. 
Different sources of data are potentially 
available. A major source of data is the 
existing medical literature. In particu-
lar, randomised controlled clinical trials 
(RCTs) are considered the most accurate 
source to assess the efﬁcacy of a treat-
ment option compared with the alterna-
tive (49). However, randomised trials 
have a number of limitations when ap-
plied to real world results, which often 
differ greatly from the carefully control-
led settings of the clinical trial. For ex-
ample, patients enrolled in RCTs gener-
ally are highly selected, the comparison 
is made with placebo rather than anoth-
er active therapy that can be of interest 
for the pharmacoeconomic analysis, the 
patient is closely monitored to ensure 
compliance with therapy. Ideally, phar-
macoeconomic evaluations should in-
corporate data on effectiveness, rather 
than on efﬁcacy, but these could be not 
available from RCTs. 
A more reliable source of data for a 
pharmacoeconomic evaluation may 
have to be drawn from more naturalis-
tic studies, such as observational stud-
ies. Alternatively, it could be worth in-
tegrating the data available from using 
additional sources, such as conducting 
additional clinical trials with a more 
naturalistic design, using data from sys-
tematic reviews of literature on effec-
tiveness (50). Nowadays, many more 
economic evaluations use data from 
different existing studies and incorpo-
rate these data into economic decision 
models (51). One main advantage of 
economic models is that they allow 
estimation of costs and consequences 
of  alternative options beyond the time 
horizon considered in a RCT (52, 53). 
Furthermore, this approach could allow 
to analyse together different data from 
different studies and to obtain more 
comprehensive estimates applicable to 
wider settings and target populations 
(54). Decision trees, Markov models, 
and Monte Carlo models are examples 
of decision models that can be used in 
the pharmacoeconomic analysis (53). 
Every model has its own advantages 
and disadvantages. The choice of the 
model to be used for an evaluation is 
based on a number of aspects that de-
pend on the economic analysis to be 
performed (55).
A further source of data that is increas-
ingly used in recent years is the admin-
istrative database (56-58). Most major 
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health agencies collect in a database all 
administrative data records to monitor 
and track services provided. Adminis-
trative databases are used to record the 
details about each individual receiving 
the service and the information on char-
acteristics of hospitalisations, medical 
consultations, drugs prescriptions, home 
care visits, diagnostic examinations. 
Among the advantages of using data 
from administrative databases, a very 
important one is that they provide data 
through extended periods of time (sev-
eral years). However, when performing 
economic analysis using administrative 
datasets some important aspects must 
be taken into account: for instance, not 
always these databases capture all di-
rect medical costs related to the target 
disease. Furthermore, they do not incor-
porate other items, such as indirect and 
intangible costs or effects. This could be 
an important limit for studies targeted to 
conditions such as those in the area of 
rheumatology, where disease and treat-
ment consequences on productivity and 
on HRQoL of the patients are particu-
larly important. 
The use of more sources of data could 
help to combine the advantages of each 
of them and overcome their limits, 
hence, to obtain more complete data for 
obtaining more reliable pharmacoeco-
nomic results.
Sensitivity analyses
There are situations where the data rele-
vant for the analyses are not complete or 
do not exist and cannot be obtained with 
the available data sources. Further un-
certainty could depend on the different 
methodologies used to analyse the data, 
on the availability of imprecise data, on 
the need to generalise results to other 
settings and countries, etc. (59). Sen-
sitivity analyses are instruments aimed 
to handle uncertainties in pharmacoeco-
nomic evaluations. They are aimed to 
assess the robustness of the assumptions 
and the impact of the uncertainty on the 
results obtained with the main analysis. 
For example, if the true values of time 
off work in a population of patients with 
RA are unknown or only a plausible 
range is known, a sensitivity analysis 
can help to understand how the uncer-
tainty signiﬁcantly impacts the results 
and how acceptable are the assumptions 
made to ﬁll the lack of data. 
Pharmacoeconomics techniques
The primary requirement of pharmac-
oeconomic evaluations is the compari-
son of two or more alternatives with 
respect of both costs and effects. This 
comparison can be carried out through 
different techniques. The main pharma-
coeconomic techniques are: Cost-Bene-
ﬁt Analysis (CBA), Cost-Effectiveness 
Analysis (CEA), Cost-Utility Analysis 
(CUA). The feature that distinguishes 
the different techniques of analysis is 
the manner in which the effects of the 
alternative options are valued.
Many studies available in literature fo-
cus only on the description of costs of a 
disease, or on a treatment for a disease. 
Cost of Illness (COI) studies or Burden 
of Illness (BOI) studies fall into this 
category (19). These studies facilitate 
description and quantiﬁcation of the so-
cio-economic impact of a target condi-
tion, from the perspective either of the 
third party payer (as regards healthcare 
costs), or of the patients (loss of pro-
ductivity, health related quality of life), 
or of the society as a whole. Estimating 
the cost of an illness can be a useful aid 
to policy decision making to underline 
the importance of a disease with respect 
to its socio-economic impact, together 
with the impact on morbidity and mor-
tality (60), when compared with the 
burden of other diseases (61). Further-
more, these studies may allow identiﬁ-
cation of drivers of costs of a disease 
and may help in the design of more 
appropriate pharmacoeconomic evalu-
ations. However, these studies cannot 
be considered as pharmacoeconomic 
evaluations, because they do not allow 
comparisons of costs and effects of al-
ternative options, hence do not allow 
identiﬁcation of programmes according 
to their relative efﬁciency. 
A method that is sometimes adopted in 
pharmacoeconomics is the cost-minimi-
sation analysis (CMA). This technique 
focuses on the comparison of costs only 
and can be applied when the alternative 
interventions are evaluated and dem-
onstrated to be equivalent in terms of 
outcomes. Hence, the economic analy-
sis can focus on the comparison of 
costs associated with each intervention. 
CMA can be identiﬁed as a subset of the 
typical pharmacoeconomic techniques, 
which are described below.
Cost-Beneﬁt Analysis
This technique was developed and ini-
tially applied in the sector of waterway 
infrastructure between the Thirties and 
Forties (62).
The technique of cost-beneﬁt analysis 
(CBA) allows to compare in monetary 
units both costs and effects of alterna-
tive programmes. The result obtained 
from a CBA typically is reported as a 
net beneﬁt, obtained from the differ-
ence between costs and effects of the 
compared alternatives. Since in CBA 
costs and effects are expressed in mon-
etary units, there are some advantages 
attributable to this technique: ﬁrst, it al-
lows assessment of all costs and effects, 
including those that are not directly re-
lated with clinical outcomes (e.g. treat-
ment satisfaction, patients’ preferences) 
and that are difﬁcult to be considered 
in the analysis if measured in different 
non-monetary units. Second, it allows 
comparison of options applicable to dif-
ferent sectors. Hence, this technique is 
straightforward to assess the allocative 
efﬁciency of investments targeted to 
different sectors (e.g. in the comparison 
of investments targeted to healthcare 
vs. public transport sectors).
While items such as drug treatment or 
hospitalisations are naturally expressed 
in monetary units, other items such 
as those related with health outcomes 
must be translated into these units, to 
be included in a CBA. There are several 
approaches to the monetary valuation 
of health outcomes: the human capital, 
revealed preferences and stated prefer-
ences of willingness to pay are among 
the most frequently used approaches 
(19, 63). However, quantifying in mon-
etary units all the effects and costs can 
be very difﬁcult and can raise some eth-
ical considerations (e.g. on the assign-
ment of a monetary value to a life).
Cost-Effectiveness Analysis
The paradigm of CEA for health and 
medical practice was published the 
ﬁrst time in 1977 in the New England 
Journal of Medicine (64). Cost-effec-
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tiveness arises from the difﬁculty in 
CBA analysis to convert all costs and 
beneﬁts attributable to the programme 
or intervention into monetary units. In 
CEA, outcomes are measured in physi-
cal units such as lives saved or life-years 
gained, disability-days averted, swollen 
and stiff joints, joint damage, functional 
capacity, Disease Activity Score, Amer-
ican College of Rheumatology response 
criteria, etc. (12, 23).
The results of a CEA are expressed as 
incremental cost-effectiveness ratio 
(ICER), corresponding to the ratio be-
tween the difference of costs of the two 
programmes (numerator) and the differ-
ence of effects of the two programmes 
(denominator). The ICER shows the 
amount of incremental cost per unit of 
additional effect. 
Since it does not require some items 
to be reported in monetary terms, CEA 
facilitates more easily conducted phar-
macoeconomic evaluations and is gen-
erally preferred to CBA. However, the 
technique of CEA presents some limits 
(as do all methods). The main prob-
lem with CEA is that it does not allow 
comparisons of programmes for which 
effects are expressed with different 
parameters, such as programmes that 
are applicable to different conditions. 
Hence, CEA does not allow to compar-
ing policy purposes across programmes 
targeted to different conditions.
Cost-Utility Analysis
Cost-Utility Analysis (CUA) was de-
veloped to overcome some of the limits 
of CEA, particularly the lack of capaci-
ty to compare interventions with effects 
reported in different units. In CUA, 
the incremental cost of a treatment is 
compared to the incremental health 
improvement attributable to the treat-
ment, in which health improvement is 
generally measured in quality-adjusted 
life-years (QALYs) gained. The results 
are expressed as incremental cost per 
QALY gained. The QALY combines life 
expectance and HRQoL by weighing 
life-years with a quality index named 
utility (43). For instance, living 2 years 
with a utility of 0.5 corresponds to one 
QALY, corresponding to the same value 
assigned to living 1 year in full health. 
The advantage of QALY as a measure 
of health outcome is that it can simul-
taneously capture gains from quantity 
and quality of life, and combine these 
into a single measure.
For this reason, the distinguishing fea-
tures of CUA are that multiple outcomes 
can be incorporated and the outcomes 
are not just measured but are valued 
according to their desirability. Because 
of the similarities between CEA and 
CUA, some authors do not distinguish 
between the two, a possible problem in 
the literature, in which CUA may ap-
pear under the label of CEA.
There are a number of situations where 
it could be worth using CUA. For in-
stance, when HRQoL is among the most 
important outcomes, such as in RA, in 
which it is difﬁcult to study mortality, 
the interest has been focused on how 
well the different programmes improve 
the patients’ physical function, social 
function, and psychological wellbeing. 
In other contexts, the programme affects 
both morbidity and mortality, which 
should be combined in a common unit 
of outcomes, such as in cancer.
Also, if the objective is to decide where 
to allocate resources between differ-
ent programmes applicable to different 
conditions (e.g. expansion of neonatal 
intensive care, treatment of hyperten-
sive patients, expansion of rehabilita-
tive services provided to post-myocar-
dial infarction patients), it is important 
to have a common unit of output for 
comparison.
However, not always QALYs data are 
available or relevant enough for the tar-
get condition. In these cases, the tech-
nique of CEA constitutes an efﬁcient 
approach to conduct the pharmacoeco-
nomic analysis of interest.
Conclusions
Use of pharmacoeconomic evaluations 
to inform health care bodies for their 
decisions is increasing. In addition, 
there is increasing interest from physi-
cians and other health care providers to 
consider both costs and beneﬁts of in-
terventions targeted to speciﬁc groups 
of patients. Given the current health-
care environment, pharmacoeconomic 
issues can sensitively condition the use 
of new and more expensive therapies in 
rheumatology. Taking these issues into 
account will help healthcare providers 
and budget holders to choose the most 
efﬁcient strategies for patients. In other 
words, pharmacoeconomic analyses 
constitute a useful tool for identifying 
the options that allow to reach satisfac-
tory results at an acceptable cost, opti-
mising the net beneﬁt deriving from the 
use of scarce resource available.
Pharmacoeconomic analyses must be 
conducted accurately to provide valu-
able information to guide the choice of 
options representing the best value for 
money without compromising the quali-
ty of care delivered (65, 66). For this rea-
son, as these analyses generally present 
some limitations, a very close and strong 
relationship between pharmacoecono-
mists and clinicians is crucial both in the 
design of pharmacoeconomic studies 
and in the interpretation of their results, 
and also in the development of more sat-
isfactory methods and indicators.
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